课题基金 / 基金详情

CLINICAL TRIAL METHODOLOGY IN SCHIZOPHRENIA

CLINICAL TRIAL METHODOLOGY IN SCHIZOPHRENIA
精神分裂症的临床试验方法
批准号:
3382410
负责人:
EUGENE M LASKA
金额:
$9.93万
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-08-01 至 1993-07-31

项目摘要

项目成果

EUGENE M LASKA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The research program we propose concerns the development of clinical trial methodology, including new experimental designs and methods of statistical analysis, for the study of antipsychotic drugs used in the treatment of schizophrenia: (1) Although "flexible dose" or "doctor's choice" designs mirror clinical practice and accommodate individual patient variations they have been seriously criticized. We will develop statistical bioassay models that estimate relative potency while taking into account placebo responders and refractory.patients as well as the dosage information. (2) When the relative potency of a test to a standard is not the same for all behavioral and side effect variables we will develop methods that permit the identification of subgroups of the variables with respect to which relative potency is constant. (3) Generally, the categories within items in a rating scale have implicit rank order quantified by arbitrarily assigning equispaced integer values to the categories. We will develop methods whereby scalar assignments are made on the basis of dose response data from the trial itself. (4) Crossover designs that are efficient and are analyzable whether or not carryover effects are present will be developed so that a relatively small sample size will have adequate power to contrast therapies. (5) Models to analyze multivariate observations for evaluation of the bioequivalence of two treatments through the simultaneous analysis of serum levels of drug and/or metabolites at all of the observation time points will be developed. (6) We shall develop statistical methodology for assessing the merits of combination therapies. The nature of the null hypothesis has led to considerable confusion in the analysis of studies of combination therapy. These usually involve hypotheses of the form HO: combinations not better than A or combination: not better than B. (7) Other statistical problems that arise in consultation and collaborating with clinical researchers will be considered.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Likely responder analysis and tests of model misspecification in randomized controlled trials of treatments for Alcohol Use Disorder
Likely responder analysis and tests of model misspecification in randomized controlled trials of treatments for Alcohol Use Disorder
Leveraging biomarkers for personalized treatment of alcohol use disorder comorbid with PTSD
Leveraging biomarkers for personalized treatment of alcohol use disorder comorbid with PTSD
海外基金